Medtronic PLC $MDT Shares Sold by Nwam LLC

Key Points

• Nwam LLC cut its Medtronic stake by 77.9% in the second quarter, selling 12,669 shares and retaining 3,604 shares valued at approximately $282,000. Institutional investors collectively own 82.06% of the company.
• Medtronic reported a quarterly earnings beat, with EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue rose 13.7% year over year, and analysts maintain a “Moderate Buy” consensus with an average price target of $103.92.
• The company declared a quarterly dividend of $0.72 per share, equivalent to $2.88 annually and a 3.1% yield. Shares recently opened at $92.87, while analyst price targets range from $83 to $118.

Nwam LLC trimmed its position in Medtronic PLC (NYSE:MDT - Free Report) by 77.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,604 shares of the medical technology company's stock after selling 12,669 shares during the quarter. Nwam LLC's holdings in Medtronic were worth $282,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MDT. Madison Asset Management LLC boosted its holdings in Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company's stock worth $18,752,000 after purchasing an additional 25,527 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of Medtronic by 0.4% in the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company's stock worth $939,009,000 after buying an additional 40,196 shares during the last quarter. Gradient Investments LLC lifted its position in shares of Medtronic by 3.9% in the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company's stock worth $38,842,000 after buying an additional 18,509 shares during the last quarter. Czech National Bank boosted its stake in shares of Medtronic by 4.7% during the 2nd quarter. Czech National Bank now owns 365,443 shares of the medical technology company's stock worth $28,589,000 after acquiring an additional 16,292 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Medtronic by 12.7% during the 4th quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company's stock valued at $75,988,000 after acquiring an additional 89,111 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on MDT shares. Piper Sandler reissued a "neutral" rating on shares of Medtronic in a research note on Monday, August 10th. Rothschild & Co Redburn lowered their price target on Medtronic from $111.00 to $106.00 and set a "buy" rating on the stock in a report on Friday, June 5th. Mizuho set a $115.00 price target on shares of Medtronic in a research report on Wednesday. The Goldman Sachs Group reduced their price objective on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $118.00 price objective on shares of Medtronic in a report on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, Medtronic has an average rating of "Moderate Buy" and an average price target of $103.92.

Medtronic Price Performance

NYSE:MDT opened at $92.87 on Friday. The stock has a market cap of $118.87 billion, a P/E ratio of 22.87, a PEG ratio of 2.16 and a beta of 0.56. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a fifty day moving average price of $86.52 and a 200 day moving average price of $85.31. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the business posted $1.26 EPS. The business's quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts anticipate that Medtronic PLC will post 5.95 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic's dividend payout ratio (DPR) is 70.94%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal first-quarter results exceeded expectations, with adjusted EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, while management raised its fiscal 2027 outlook to approximately $5.94-$6.00 in EPS. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Analysts responded favorably to the earnings beat and raised guidance. RBC reaffirmed its Outperform rating with a $118 price target, while TD Cowen maintained a Buy rating; other firms also increased their targets. Medtronic Analysts Raise Their Forecasts
• Positive Sentiment: Management highlighted broad-based growth across major franchises and newer platforms, including robotics and ablation. Investors view this as evidence that Medtronic’s multiyear growth recovery may be gaining momentum. MDT Earnings Call Focuses on Broad Growth
• Positive Sentiment: A PERSIST addendum study is generating additional real-world evidence for Medtronic’s Inceptiv spinal cord stimulation system, potentially strengthening physician adoption and investor confidence. Medtronic’s PERSIST Study
• Positive Sentiment: Medtronic entered a strategic partnership with Cornerstone Robotics intended to expand global access to robot-assisted surgery, supporting its long-term robotics strategy. Cornerstone Robotics Partnership
• Negative Sentiment: Market strategists warned that Medtronic has become a crowded healthcare-sector trade. The recommendation included using options to bet on a decline, reflecting concern that excessive bullish positioning could limit further gains or trigger a pullback. Crowded Healthcare Stocks

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Kiil sold 4,189 shares of the company's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company's stock, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.27% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source